Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Biorxiv : the Preprint Server for Biology
|
June 25, 2024
Directed evolution of hyperactive integrases for site specific insertion of transgenes
Brian E Hew, Sabranth Gupta, Ryuei Sato, et al.
Nucleic Acids Research
|
July 2, 2024
Directed evolution of hyperactive integrases for site specific insertion of transgenes
Brian E Hew, Sabranth Gupta, Ryuei Sato, et al.
Cancer Medicine
|
January 24, 2013
Significance of lymphovascular space invasion in epithelial ovarian cancer
Koji Matsuo, Todd B Sheridan, Kiyoshi Yoshino, et al.
Advances in Experimental Medicine and Biology
|
November 26, 2008
Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents
David C Fritzinger, Brian E Hew, June Q Lee, et al.
Biorxiv : the Preprint Server for Biology
|
September 26, 2025
Gene-sized DNA insertion at genomic safe harbors in human cells using a site-directed transposase
James E Short, Lisa Sharek, Joshua F Meckler, et al.
Nucleic Acids Research
|
December 8, 2025
Gene-sized DNA insertion at genomic safe harbors in human cells using a site-directed transposase
James E Short, Lisa Sharek, Joshua F Meckler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2018
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells
Fiona Simpkins, Kibeom Jang, Hyunho Yoon, et al.
Biorxiv : the Preprint Server for Biology
|
April 27, 2026
The exocyst is an insulin-sensitive regulator of amyloid precursor protein trafficking and amyloid-beta generation in neurons
Chantell Balaan, Geetika Y Patwardhan, Rachel K Sachs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2015
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer
Karina E Hew, Philip C Miller, Dorraya El-Ashry, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Biorxiv : the Preprint Server for Biology
|
June 25, 2024
Directed evolution of hyperactive integrases for site specific insertion of transgenes
Brian E Hew, Sabranth Gupta, Ryuei Sato, et al.
Nucleic Acids Research
|
July 2, 2024
Directed evolution of hyperactive integrases for site specific insertion of transgenes
Brian E Hew, Sabranth Gupta, Ryuei Sato, et al.
Cancer Medicine
|
January 24, 2013
Significance of lymphovascular space invasion in epithelial ovarian cancer
Koji Matsuo, Todd B Sheridan, Kiyoshi Yoshino, et al.
Advances in Experimental Medicine and Biology
|
November 26, 2008
Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents
David C Fritzinger, Brian E Hew, June Q Lee, et al.
Biorxiv : the Preprint Server for Biology
|
September 26, 2025
Gene-sized DNA insertion at genomic safe harbors in human cells using a site-directed transposase
James E Short, Lisa Sharek, Joshua F Meckler, et al.
Nucleic Acids Research
|
December 8, 2025
Gene-sized DNA insertion at genomic safe harbors in human cells using a site-directed transposase
James E Short, Lisa Sharek, Joshua F Meckler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2018
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells
Fiona Simpkins, Kibeom Jang, Hyunho Yoon, et al.
Biorxiv : the Preprint Server for Biology
|
April 27, 2026
The exocyst is an insulin-sensitive regulator of amyloid precursor protein trafficking and amyloid-beta generation in neurons
Chantell Balaan, Geetika Y Patwardhan, Rachel K Sachs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2015
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer
Karina E Hew, Philip C Miller, Dorraya El-Ashry, et al.
Page
of 4